The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels
Open accessAbstract
BACKGROUND: In patients with coronary heart disease and a broad range of cholesterol levels, cholesterol-lowering therapy reduces the risk of coronary events, but the effects on mortality from coronary heart disease and overall mortality have remained uncertain. METHODS: In a double-blind, randomized trial, we compared the effects of pravastatin (40 mg daily) with those of a placebo over a mean follow-up period of 6.1 years in 9014 patients who were 31 to 75 years of age. The patients had a history of myocardial infarction or hospitalization for unstable angina and initial plasma total cholesterol levels of 155 to 271 mg per deciliter. Both groups received advice on following a cholesterol-lowering diet. The primary study outcome was mortality from coronary heart disease. RESULTS: Death from coronary heart disease occurred in 8.3 percent of the patients in the placebo group and 6.4 percent of those in the pravastatin group, a relative reduction in risk of 24 percent (95 percent confidence interval, 12 to 35 percent; P<0.001). Overall mortality was 14.1 percent in the placebo group and 11.0 percent in the pravastatin group (relative reduction in risk, 22 percent; 95 percent confidence interval, 13 to 31 percent; P<0.001). The incidence of all cardiovascular outcomes was consistently lower among patients assigned to receive pravastatin; these outcomes included myocardial infarction (reduction in risk, 29 percent; P<0.001), death from coronary heart disease or nonfatal myocardial infarction (a 24 percent reduction in risk, P<0.001), stroke (a 19 percent reduction in risk, P=0.048), and coronary revascularization (a 20 percent reduction in risk, P<0.001). The effects of treatment were similar for all predefined subgroups. There were no clinically significant adverse effects of treatment with pravastatin. CONCLUSIONS: Pravastatin therapy reduced mortality from coronary heart disease and overall mortality, as compared with the rates in the placebo group, as well as the incidence of all prespecified cardiovascular events in patients with a history of myocardial infarction or unstable angina who had a broad range of initial cholesterol levels.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A large body of evidence indicates that statin-based strategies convey similar LDL-C lowering and relative cardiovascular risk reduction in patients with and those without T2DM.102–112”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [103]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Data from RCTs and meta-analyses indicate that routine early use of high-intensity statin therapy is associated with rapid and sustained clinical benefits [438-442].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [442]
Experimental — accuracy not yet measuredIn the citing paper
“Although healthy lifestyle habits remain a cornerstone of T2DM management, trial data have confirmed the additional benefits of statin therapy in the primary and secondary prevention of CAD.13,102–112”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [103]
In the citing paper
“Pooling of results from RCTs suggested that cholesterol lowering with statin treatment reduced incident HF by 9-45% in patients with CAD.22,180”
From ESC/EAS Guidelines for the management of dyslipidaemias (2011) · cites this paper as [22]
In the citing paper
“Pooling of results from RCTs suggested that cholesterol lowering with statin treatment reduced incident HF by 9-45% in patients with CAD. 368,369”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [369]
In the citing paper
“Pooling of results from RCTs suggested that cholesterol lowering with statin treatment reduced incident HF by 9e45% in patients with CAD.368,369”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [369]
In the citing paper
“It was demonstrated in the REACH registry, a registry study on patients with ASCVD or overlapping risks factors for ASCVD, that approximately 16% registered cases are complicated with two or more ASCVD757).”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [757]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Statistical Methods for Survival Data Analysis.
Lachenbruch, P. A., & Lee, E. T. (1993) · Journal of the American Statistical Association · doi:10.2307/2290742 · Cited by 2,851
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1976) · British Journal of Cancer · doi:10.1038/bjc.1976.220 · Cited by 2,294
Muldoon, M. F., Manuck, S. B., & Matthews, K. A. (1990) · BMJ · doi:10.1136/bmj.301.6747.309 · Cited by 960
EUROASPIRE Study Group (1997) · European Heart Journal · doi:10.1093/oxfordjournals.eurheartj.a015136 · Cited by 665
Chen, Z., Peto, R., Collins, R., MacMahon, S. W., Lu, J., & Li, W. (1991) · BMJ · doi:10.1136/bmj.303.6797.276 · Cited by 537
Research works printed but not linked: 4
- Peto R, 1985, Circulation, 72, 451
- Keech A, 1992, Postgrad Med J, 68, 870
- 1994, Lancet, 344, 1383
- Keech A, 1998, Atherosclerosis, 136, S31
Cited by
Sorted by citations
Items 501–600 of 1,037
Vyas, A. K., Guo, H., Moss, A. J., Olshansky, B., McNitt, S. A., Hall, W. J., Zaręba, W., Steinberg, J. S., Fischer, A., Ruskin, J. N., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.09.053 · Cited by 175
Users' Guides to the Medical Literature
McAlister, F. A., Laupacis, A., Wells, G. A., Sackett, D. L., & for the Evidence-Based Medicine Working Group (1999) · JAMA · doi:10.1001/jama.282.14.1371 · Cited by 175
Discontinuation of Statin Therapy and Clinical Outcome After Ischemic Stroke
Colivicchi, F., Bassi, A., Santini, M., & Caltagirone, C. (2007) · Stroke · doi:10.1161/strokeaha.107.487017 · Cited by 174
Matthan, N. R., Pencina, M. J., LaRocque, J. M., Jacques, P. F., D’Agostino, R. B., Schaefer, E. J., & Lichtenstein, A. H. (2009) · Journal of Lipid Research · doi:10.1194/jlr.p900039-jlr200 · Cited by 174
Pelat, M., Dessy, C., Massion, P. B., Desager, J., Féron, O., & Balligand, J. (2003) · Circulation · doi:10.1161/01.cir.0000065601.83526.3e · Cited by 174
Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia
Musiał, J., Undas, A., Gajewski, P., Jankowski, M., Sydor, W., & Szczeklik, A. (2001) · International Journal of Cardiology · doi:10.1016/s0167-5273(00)00439-3 · Cited by 174
Supplement to the Guidelines for the Management of Transient Ischemic Attacks
Albers, G. W., Hart, R. G., Lutsep, H. L., Newell, D. W., & Sacco, R. L. (1999) · Stroke · doi:10.1161/01.str.30.11.2502 · Cited by 174
Pharmacotherapy for dyslipidaemia ? current therapies and future agents
Bays, H. E., & Stein, E. A. (2003) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.4.11.1901 · Cited by 173
Tenenbaum, A., & Fisman, E. Z. (2012) · Cardiovascular Diabetology · doi:10.1186/1475-2840-11-125 · Cited by 172
Feringa, H. H. H., van Waning, V. H., Bax, J. J., Elhendy, A., Boersma, E. H., Schouten, O., Galal, W., Vidaković, R., Tangelder, M. J. D., & Poldermans, D. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.09.074 · Cited by 172
Barrett-Connor, E. L., Giardina, E. V., Gitt, A. K., Gudat, U., Steinberg, H. O., & Tschoepe, D. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.9.934 · Cited by 171
Aukrust, P., Gullestad, L. L., Ueland, T., Damås, J. K., & Yndestad, A. (2005) · Annals of Medicine · doi:10.1080/07853890510007232 · Cited by 171
Sassano, A., & Platanias, L. C. (2008) · Cancer Letters · doi:10.1016/j.canlet.2007.11.036 · Cited by 171
Chow, B. J. W., Small, G. R., Yam, Y., Chen, L., McPherson, R., Achenbach, S. S., Al-Mallah, M. H., Berman, D. S., Budoff, M. J., Cademartiri, F., et al. (2015) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.114.304351 · Cited by 171
Statin therapy is associated with improved patency of autogenous infrainguinal bypass grafts
Abbruzzese, T. A., Havens, J. M., Belkin, M., Donaldson, M. C., Whittemore, A. D., Liao, J. K., & Conte, M. S. (2004) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2003.12.027 · Cited by 171
Patient Knowledge of Coronary Risk Profile Improves the Effectiveness of Dyslipidemia Therapy
Grover, S. A. (2007) · Archives of Internal Medicine · doi:10.1001/archinte.167.21.2296 · Cited by 171
Long-Term Use of Cardiovascular Drugs
Rosselló, X., Pocock, S., & Julian, D. G. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.07.018 · Cited by 171
Rosuvastatin: A Review of the Pharmacology and Clinical Effectiveness in Cardiovascular Disease
Luvai, A., Mbagaya, W., Hall, A. S., & Barth, J. H. (2012) · Clinical Medicine Insights Cardiology · doi:10.4137/cmc.s4324 · Cited by 170
Toward “Pain-Free” Statin Prescribing: Clinical Algorithm for Diagnosis and Management of Myalgia
Jacobson, T. A. (2008) · Mayo Clinic Proceedings · doi:10.4065/83.6.687 · Cited by 170
Krumholz, H. M., Anderson, J. L., Bachelder, B. L., Fesmire, F. M., Fihn, S. D., Foody, J. M., Ho, P. M., Kosiborod, M., Masoudi, F. A., & Nallamothu, B. K. (2008) · Circulation · doi:10.1161/circulationaha.108.191099 · Cited by 170
Federman, A. D. (2001) · JAMA · doi:10.1001/jama.286.14.1732 · Cited by 170
Yeganeh, B., Wiecheć, E., Ande, S. R., Sharma, P. K., Moghadam, A. R., Post, M., Freed, D. H., Hashemi, M. M., Shojaei, S., Zeki, A. A., et al. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.02.007 · Cited by 169
Vale, M., Jelinek, M. V., Best, J. D., & Santamaria, J. D. (2002) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(01)00460-7 · Cited by 169
Delahoy, P. J., Magliano, D. J., Webb, K., Grobler, M. P., & Liew, D. (2009) · Clinical Therapeutics · doi:10.1016/j.clinthera.2009.02.017 · Cited by 169
Effects of Early Treatment With Statins on Short-term Clinical Outcomes in Acute Coronary Syndromes
Briel, M., Schwartz, G. G., Thompson, P. L., de Lemos, J. A., Blazing, M. A., van Es, G., Kayıkçıoğlu, M., Arntz, H.-R., den Hartog, F. R., Veeger, N. J. G. M., et al. (2006) · JAMA · doi:10.1001/jama.295.17.2046 · Cited by 169
Markers of inflammation and their clinical significance
Ballantyne, C. M., & Nambi, V. (2005) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2005.02.005 · Cited by 168
Louis, A. A., Cleland, J. G. F., Crabbe, S., Ford, S., Thackray, S. D. R., Houghton, T., & Clark, A. L. (2001) · European Journal of Heart Failure · doi:10.1016/s1388-9842(01)00149-0 · Cited by 168
Rief, W., Avorn, J., & Barsky, A. J. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.2.155 · Cited by 167
Beyond aspirin—cancer prevention with statins, metformin and bisphosphonates
Gronich, N., & Rennert, G. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.169 · Cited by 167
LaCroix, A. Z., Cauley, J. A., Pettinger, M. B., Hsia, J., Bauer, D. C., McGowan, J., Chen, Z., Lewis, C. E., McNeeley, S. G., Passaro, M. D., et al. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-2-200307150-00009 · Cited by 167
2017 Taiwan lipid guidelines for high risk patients
Li, Y., Ueng, K., Jeng, J., Charng, M., Lin, T., Chien, K., Wang, C., Chao, T., Liu, P., Su, C., et al. (2017) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2016.11.013 · Cited by 166
Vergouwen, M. D. I., de Haan, R. J., Vermeulen, M., & Roos, Y. B. W. E. M. (2008) · Stroke · doi:10.1161/strokeaha.107.488791 · Cited by 166
Improved Survival of Diabetic Foot Ulcer Patients 1995–2008
Young, M. J., McCardle, J., Randall, L. E., & Barclay, J. (2008) · Diabetes Care · doi:10.2337/dc08-1242 · Cited by 165
Influenza vaccine as a coronary intervention for prevention of myocardial infarction
MacIntyre, C. R., Mahimbo, A., Moa, A., & Barnes, M. (2016) · Heart · doi:10.1136/heartjnl-2016-309983 · Cited by 165
Griel, A. E., Cao, Y., Bagshaw, D., Cifelli, A. M., Holub, B. J., & Kris‐Etherton, P. M. (2008) · Journal of Nutrition · doi:10.1093/jn/138.4.761 · Cited by 165
Clinical Pharmacokinetics of Fluvastatin
Scripture, C. D., & Pieper, J. A. (2001) · Clinical Pharmacokinetics · doi:10.2165/00003088-200140040-00003 · Cited by 165
Matsuzaki, M., Hiramori, K., Imaizumi, T., Kitabatake, A., Hishida, H., Nomura, M., Fujii, T., Sakuma, I., Fukami, K., Honda, T., et al. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)01955-1 · Cited by 165
Kinlay, S. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.01.083 · Cited by 164
Diabetes and Cardiovascular Disease
Resnick, H. E., & Howard, B. V. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.103904 · Cited by 165
Disposition of the Selective Cholesterol Absorption Inhibitor Ezetimibe in Healthy Male Subjects
Patrick, J. E., Kosoglou, T., Stauber, K. L., Alton, K. B., Maxwell, S. E., Zhu, Y., Statkevich, P., Iannucci, R., Chowdhury, S. K., Affrime, M. B., et al. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.4.430 · Cited by 164
Ferris, A., Robertson, R. M., Fabunmi, R. P., & Mosca, L. J. (2005) · Circulation · doi:10.1161/01.cir.0000157745.46344.a1 · Cited by 163
Wright, R. S., Collins, M. G., Stoekenbroek, R. M., Robson, R. A., Wijngaard, P. L. J., Landmesser, U., Leiter, L. A., Kastelein, J. J. P., Ray, K. K., & Kallend, D. G. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2019.08.021 · Cited by 163
Devaraj, S., & Jialal, I. (2000) · Circulation · doi:10.1161/01.cir.102.2.191 · Cited by 163
Behaviour of some indicators of oxidative stress in postmenopausal and fertile women
Signorelli, S. S., Neri, S., Sciacchitano, S., Pino, L. D., Costa, M. P., Marchese, G., Celotta, G., Cassibba, N., Pennisi, G., & Caschetto, S. (2005) · Maturitas · doi:10.1016/j.maturitas.2005.03.001 · Cited by 163
Huang, E. S., Meigs, J. B., & Singer, D. E. (2001) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)00978-0 · Cited by 163
C-reactive protein and cardiovascular disease: a review of risk prediction and interventions
de Ferranti, S. D., & Rifai, N. (2002) · Clinica Chimica Acta · doi:10.1016/s0009-8981(01)00797-5 · Cited by 162
Oral l -Arginine in Patients With Coronary Artery Disease on Medical Management
Blum, A., Hathaway, L., Mincemoyer, R., Schenke, W. H., Kirby, M., Csákó, G., Waclawiw, M. A., Panza, J. A., & Cannon, R. O. (2000) · Circulation · doi:10.1161/01.cir.101.18.2160 · Cited by 162
Differential Effects of Lipid-Lowering Therapies on Stroke Prevention
Corvol, J., Bouzamondo, A., Sirol, M., Hulot, J., Sanchez-Peña, P., & Lechat, P. P. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.6.669 · Cited by 162
Reith, C., Preiss, D., Blackwell, L., Emberson, J., Spata, E., Davies, K., Halls, H., Harper, C., Holland, L., Wilson, K., et al. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00040-8 · Cited by 161
Simes, J. R., Robledo, K. P., White, H. D., Espinoza, D., Stewart, R., SULLIVAN, D. R., Zeller, T., Hague, W. E., Nestel, P. J., Glasziou, P., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.029901 · Cited by 161
Demographics and concomitant disorders in heart failure
Krum, H., & Gilbert, R. E. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13869-x · Cited by 161
Hanefeld, M., Marx, N., Pfützner, A., Baurecht, W., Lübben, G., Karagiannis, E., Stier, U., & Forst, T. M. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.08.054 · Cited by 161
Primatesta, P., & Poulter, N. R. (2000) · BMJ · doi:10.1136/bmj.321.7272.1322 · Cited by 161
Selecting Indicators for the Quality of Cardiac Care at the Health Systems Level in OECD Countries
Lambie, L., & Mattke, S. (2004) · OECD health technical papers · doi:10.1787/230016103828 · Cited by 161
Preiss, D., Campbell, R. T., Murray, H. M., Ford, I., Packard, C. J., Sattar, N., Rahimi, K., Colhoun, H. M., Waters, D. D., LaRosa, J. C., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv072 · Cited by 160
Jafri, H., Alsheikh-Ali, A. A. A., & Karas, R. H. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.12.069 · Cited by 160
Gullestad, L. L., Ueland, T., KJEKSHUS, J. K., Nymo, S. H., Hulthe, J., Muntendam, P., Adourian, A. S., Böhm, M., van Veldhuisen, D. J., Michel Komajda, N., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs077 · Cited by 160
Understanding the molecular mechanisms of statin pleiotropic effects
German, C. A., & Liao, J. K. (2023) · Archives of Toxicology · doi:10.1007/s00204-023-03492-6 · Cited by 160
Cholesterol lowering and endothelial function
Vogel, R. A. (1999) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)00261-2 · Cited by 160
Vecchione, C., & Brandes, R. P. (2002) · Circulation Research · doi:10.1161/01.res.0000028004.76218.b8 · Cited by 160
Effect of pravastatin in people with diabetes and chronic kidney disease
Tonelli, M., Keech, A., Shepherd, J., Sacks, F., Tonkin, A., Packard, C., Pfeffer, M., Simes, J., Isles, C., Furberg, C., et al. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005070779 · Cited by 159
Heart failure: epidemiology and prevention in India.
Huffman, M. D., & Prabhakaran, D. (2010) · PubMed · Cited by 159
Statins and the Risk of Lung, Breast, and Colorectal Cancer in the Elderly
Setoguchi, S., Glynn, R. J., Avorn, J., Mogun, H., & Schneeweiß, S. (2006) · Circulation · doi:10.1161/circulationaha.106.650176 · Cited by 158
McKenney, J. M., Jones, P. H., Adamczyk, M. A., Cain, V. A., Bryzinski, B. S., Blasetto, J. W., & for the STELLAR Study Group (2003) · Current Medical Research and Opinion · doi:10.1185/030079903125002405 · Cited by 158
Brewer, H. B. (1999) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)00308-2 · Cited by 158
Arntz, H.-R., Agrawal, R., Wunderlich, W., Schnitzer, L., Stern, R., Fischer, F., & Schultheiß, H. (2000) · The American Journal of Cardiology · doi:10.1016/s0002-9149(00)01230-3 · Cited by 158
Cholesterol and the Risk of Ischemic Stroke
Bowman, T. S., Sesso, H. D., Ma, J., Kurth, T., Kase, C. S., Stampfer, M. J., & Gaziano, J. M. (2003) · Stroke · doi:10.1161/01.str.0000102171.91292.dc · Cited by 157
Wanner, C., Krane, V., März, W., Olschewski, M., Asmus, H.-G., Krämer, W., Kühn, K.-W., Kütemeyer, H., Mann, J. F. E., Ruf, G., et al. (2004) · Kidney and Blood Pressure Research · doi:10.1159/000080241 · Cited by 157
Early vascular benefits of statin therapy
Tsiara, S., Elisaf, M., & Mikhailidis, D. P. (2003) · Current Medical Research and Opinion · doi:10.1185/030079903125002225 · Cited by 157
Chauvin, B., Drouot, S., Barrail‐Tran, A., & Taburet, A. (2013) · Clinical Pharmacokinetics · doi:10.1007/s40262-013-0075-4 · Cited by 156
Brown, W. V., Bays, H. E., Hassman, D. R., McKenney, J. M., Chitra, R., Hutchinson, H. G., & Miller, E. (2002) · American Heart Journal · doi:10.1067/mhj.2002.129312 · Cited by 156
Dyslipidemia in the metabolic syndrome and type 2 diabetes mellitus.
Brunzell, J. D., & Ayyobi, A. F. (2003) · The American Journal of Medicine · doi:10.1016/j.amjmed.2003.08.011 · Cited by 155
Comparative Effectiveness of Generic and Brand-Name Statins on Patient Outcomes: A Cohort Study
Gagne, J. J., Choudhry, N. K., Kesselheim, A. S., Polinski, J. M., Hutchins, D., Matlin, O. S., Brennan, T. A., Avorn, J., & Shrank, W. H. (2014) · Annals of Internal Medicine · doi:10.7326/m13-2942 · Cited by 155
Davidson, M. H., Corson, M. A., Alberts, M. J., Anderson, J. L., Gorelick, P. B., Jones, P. H., Lerman, A., McConnell, J. P., & WEINTRAUB, H. S. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.04.019 · Cited by 155
Withdrawal of Statin Treatment Abrogates Stroke Protection in Mice
Gertz, K. R., Laufs, U., Lindauer, U., Nickenig, G., Böhm, M., Dirnagl, U., & Endres, M. (2003) · Stroke · doi:10.1161/01.str.0000054055.28435.bf · Cited by 155
Napoli, P. D. (2001) · Cardiovascular Research · doi:10.1016/s0008-6363(01)00306-6 · Cited by 155
Simvastatin triggers mitochondria-induced Ca2+ signaling alteration in skeletal muscle
Sirvent, P., Mercier, J., Vassort, G., & Lacampagne, A. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.02.070 · Cited by 154
Early Statin Initiation and Outcomes in Patients With Acute Coronary Syndromes
Newby, L. K. (2002) · JAMA · doi:10.1001/jama.287.23.3087 · Cited by 154
Continuation of Statin Treatment and All-Cause Mortality
Shalev, V., Chodick, G., Silber, H., Kokia, E. S., Jan, J., & Heymann, A. D. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2008.552 · Cited by 153
LDL-C does not cause cardiovascular disease: a comprehensive review of the current literature
Ravnskov, U., de Lorgeril, M., Diamond, D. M., Hama, R., Hamazaki, T., Hammarskjöld, B., Hynes, N., Kendrick, M. E., Langsjoen, P. H., Mascitelli, L., et al. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1519391 · Cited by 153
Malhotra, H. S., & Goa, K. L. (2001) · Drugs · doi:10.2165/00003495-200161120-00012 · Cited by 153
The ENCORE Investigators (2003) · Circulation · doi:10.1161/01.cir.0000046488.52939.bf · Cited by 153
The Effect of Medicare Part D on Drug and Medical Spending
Zhang, Y., Donohue, J. M., Lave, J. R., O'Donnell, G., & Newhouse, J. P. (2009) · New England Journal of Medicine · doi:10.1056/nejmsa0807998 · Cited by 152
KJEKSHUS, J. K., Dunselman, P., Blideskog, M., Eskilson, C., Hjalmarson, Å. C., McMurray, J. J. V., Waagstein, F., Wedel, H., Wessman, P., & Wikstrand, J. (2005) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2005.09.005 · Cited by 152
Apolipoprotein Concentrations During Treatment and Recurrent Coronary Artery Disease Events
van Lennep, J. E. R., Westerveld, H. T., van Lennep, H. W. O. R., Zwinderman, A. H., Erkelens, D. W., & van der Wall, E. E. (2000) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.20.11.2408 · Cited by 152
Backer, G. D., Ambrosio, G., Borch‐Johnsen, K., Brotons, C., Cífková, R., Dallongeville, J., Ebrahim, S. B. J., Færgeman, O., Graham, I. D., Mancia, G., et al. (2003) · PubMed · doi:10.1097/01.hjr.0000087913.96265.e2 · Cited by 153
Interventions to improve adherence to lipid lowering medication
Schedlbauer, A., Davies, P. A., & Fahey, T. P. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004371.pub3 · Cited by 152
Statins as antiinflammatory and immunomodulatory agents: A future in rheumatologic therapy?
Abeles, A. M., & Pillinger, M. H. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21521 · Cited by 151
Coronary Heart Disease in African Americans
Clark, L. T., Ferdinand, K. C., Flack, J. M., Gavin, J. R., Hall, W. D., Kumanyika, S., Reed, J. W., Saunders, E., Valantine, H. A., Watson, K. E., et al. (2001) · Heart Disease · doi:10.1097/00132580-200103000-00007 · Cited by 151
Sadowitz, B. D., Maier, K. G., & Gahtan, V. (2010) · Vascular and Endovascular Surgery · doi:10.1177/1538574410362922 · Cited by 150
Statins as Regulators of Redox State in the Vascular Endothelium: Beyond Lipid Lowering
Margaritis, M., Channon, K. M., & Antoniades, C. A. (2013) · Antioxidants and Redox Signaling · doi:10.1089/ars.2013.5430 · Cited by 149
Hypertriglyceridemia and cardiovascular risk reduction
Jacobson, T. A., Miller, M. J., & Schaefer, E. J. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.05.002 · Cited by 149
Ineffective Secondary Prevention in Survivors of Cardiovascular Events in the US Population
Qureshi, A. I., Suri, M. F. K., Guterman, L. R., & Hopkins, L. N. (2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.13.1621 · Cited by 149
Cardiovascular effects of statins, beyond lipid-lowering properties
Mihos, C. G., Pineda, A. M., & Santana, O. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2014.02.009 · Cited by 148
Cholesterol reduction yields clinical benefits: meta-analysis including recent trials
Gould, A. L., Davies, G., Alemao, E., Yin, D., & Cook, J. R. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.05.012 · Cited by 147
Pedersen, T. R., & Tobert, J. A. (2004) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.5.12.2583 · Cited by 147
Redfern, J., Briffa, T. G., Ellis, E. M., & Freedman, B. (2008) · Heart · doi:10.1136/hrt.2008.150870 · Cited by 147
Frambach, S. J. C. M., de Haas, R., Smeitink, J. A. M., Rongen, G. A. P. J. M., Rüssel, F. G. M., & Schirris, T. J. J. (2019) · Pharmacological Reviews · doi:10.1124/pr.119.017897 · Cited by 146
Kotzka, J., Müller-Wieland, D., Roth, G., Kremer, L., Munck, M., Schürmann, S., Knebel, B., & Krone, W. (2000) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)32079-4 · Cited by 146
Perreault, S., Blais, L., Lamarre, D., Dragomir, A., Berbiche, D., Lalonde, L., Laurier, C., St-Maurice, F., & Collin, J. (2005) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2005.02355.x · Cited by 146
Metadata
- Authors
- The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group
- Affiliations
- The University of Sydney (AU)
- Corresponding author
- The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1998-11-05
- Volume
- 339
- Issue
- 19
- Pages
- 1349-1357
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W38523360
- Cited by
- 5,261
- References
- 21
- Citations by year
- 2026: 19 · 2025: 24 · 2024: 57 · 2023: 53 · 2022: 60 · 2021: 58 · 2020: 72 · 2019: 82 · 2018: 81 · 2017: 94 · 2016: 114 · 2015: 111 · 2014: 118 · 2013: 167 · 2012: 147
- FWCI
- 312.19
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Keywords
- pravastatin, coronary artery disease, statin therapy, cholesterol-lowering therapy, cardiovascular mortality, myocardial infarction, unstable angina, stroke, coronary revascularization, total cholesterol, secondary prevention, lipid-lowering diet
- MeSH terms
- Adult, Aged, Anticholesteremic Agents, Cardiovascular Diseases, Coronary Disease, Double-Blind Method, Female, Humans, Lipids, Male, Middle Aged, Mortality, Myocardial Infarction, Risk, Incidence, Pravastatin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
